Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies (Q45746959)

15 December 2017

title

Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies (English)

1 reference

15 December 2017

1 reference

Notka F

1

1 reference

15 December 2017

Stahl-Hennig C

2

1 reference

15 December 2017

Dittmer U

3

1 reference

15 December 2017

Wolf H

4

1 reference

15 December 2017

Wagner R

5

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 September 1999

1 reference

15 December 2017

published in

Vaccine

1 reference

15 December 2017

volume

18

1 reference

15 December 2017

issue

3-4

1 reference

15 December 2017

page(s)

291-301

1 reference

15 December 2017

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Measuring vaccine-induced HIV neutralization: report of a workshop.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

1 reference

7 January 2021

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Clearance of HIV infection in a perinatally infected infant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Can the immune response control HIV infection?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

CD8+ cell anti-HIV activity: nonlytic suppression of virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Utility of SHIV for testing HIV-1 vaccine candidates in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

A new generation of animal cell expression vectors based on the Semliki Forest virus replicon

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Semliki Forest virus expression system: production of conditionally infectious recombinant particles.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Early helper T-cell dysfunction in simian immunodeficiency virus but not in human immunodeficiency virus type-2-infected macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Simian immunodeficiency virus (SIV) gp130 oligomers protect rhesus macaques (Macaca mulatta) against the infection with SIVmac32H grown on T-cells or derived ex vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

Progress in the development of an HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900200-5

7 January 2021

10.1016/S0264-410X(99)00200-5

Identifiers

DOI

1 reference

15 December 2017

PubMed ID

10506654

1 reference

15 December 2017